Dane Leone
Stock Analyst at Raymond James
(1.51)
# 3,035
Out of 4,829 analysts
88
Total ratings
53.85%
Success rate
-4.29%
Average return
Main Sectors:
Stocks Rated by Dane Leone
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| XLO Xilio Therapeutics | Maintains: Outperform | $6 → $4 | $0.73 | +447.20% | 3 | Nov 8, 2024 | |
| RGNX REGENXBIO | Reinstates: Outperform | $45 | $7.97 | +464.62% | 2 | Feb 21, 2024 | |
| BPMC Blueprint Medicines | Maintains: Strong Buy | $85 → $100 | $100.27 | -0.27% | 9 | Dec 22, 2023 | |
| RVMD Revolution Medicines | Initiates: Outperform | $30 | $41.88 | -28.37% | 1 | Nov 16, 2023 | |
| BLUE bluebird bio | Maintains: Outperform | $200 → $260 | $3.29 | +7,802.74% | 6 | Nov 8, 2023 | |
| REGN Regeneron Pharmaceuticals | Upgrades: Outperform | $950 | $575.63 | +65.04% | 10 | Nov 3, 2023 | |
| NKTX Nkarta | Upgrades: Strong Buy | $13 | $2.02 | +543.56% | 5 | Oct 18, 2023 | |
| BBIO BridgeBio Pharma | Maintains: Outperform | $29 → $46 | $35.68 | +28.92% | 2 | Jul 18, 2023 | |
| GLPG Galapagos NV | Upgrades: Outperform | $69 | $25.07 | +175.23% | 5 | May 8, 2023 | |
| RLAY Relay Therapeutics | Upgrades: Strong Buy | $29 | $3.11 | +832.48% | 2 | Apr 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $5 → $8 | $2.01 | +298.01% | 2 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $29 → $14 | $7.39 | +89.57% | 5 | Nov 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Strong Buy | $58 | $8.77 | +561.35% | 4 | Oct 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $54 → $70 | $30.82 | +127.13% | 3 | Aug 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.17 | - | 6 | Aug 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $54 → $63 | $32.13 | +96.08% | 2 | Aug 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $48.18 | - | 4 | Jun 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.96 | - | 2 | Apr 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $50 → $65 | $44.20 | +47.06% | 3 | Oct 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $6.75 | - | 5 | Dec 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $255 | $274.76 | -7.19% | 3 | Oct 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $32 | $3.35 | +855.22% | 2 | Sep 10, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | n/a | $154.14 | - | 2 | Jul 21, 2017 |
Xilio Therapeutics
Nov 8, 2024
Maintains: Outperform
Price Target: $6 → $4
Current: $0.73
Upside: +447.20%
REGENXBIO
Feb 21, 2024
Reinstates: Outperform
Price Target: $45
Current: $7.97
Upside: +464.62%
Blueprint Medicines
Dec 22, 2023
Maintains: Strong Buy
Price Target: $85 → $100
Current: $100.27
Upside: -0.27%
Revolution Medicines
Nov 16, 2023
Initiates: Outperform
Price Target: $30
Current: $41.88
Upside: -28.37%
bluebird bio
Nov 8, 2023
Maintains: Outperform
Price Target: $200 → $260
Current: $3.29
Upside: +7,802.74%
Regeneron Pharmaceuticals
Nov 3, 2023
Upgrades: Outperform
Price Target: $950
Current: $575.63
Upside: +65.04%
Nkarta
Oct 18, 2023
Upgrades: Strong Buy
Price Target: $13
Current: $2.02
Upside: +543.56%
BridgeBio Pharma
Jul 18, 2023
Maintains: Outperform
Price Target: $29 → $46
Current: $35.68
Upside: +28.92%
Galapagos NV
May 8, 2023
Upgrades: Outperform
Price Target: $69
Current: $25.07
Upside: +175.23%
Relay Therapeutics
Apr 19, 2023
Upgrades: Strong Buy
Price Target: $29
Current: $3.11
Upside: +832.48%
Nov 10, 2022
Maintains: Outperform
Price Target: $5 → $8
Current: $2.01
Upside: +298.01%
Nov 8, 2022
Maintains: Strong Buy
Price Target: $29 → $14
Current: $7.39
Upside: +89.57%
Oct 13, 2022
Upgrades: Strong Buy
Price Target: $58
Current: $8.77
Upside: +561.35%
Aug 29, 2022
Maintains: Outperform
Price Target: $54 → $70
Current: $30.82
Upside: +127.13%
Aug 10, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $1.17
Upside: -
Aug 5, 2022
Maintains: Outperform
Price Target: $54 → $63
Current: $32.13
Upside: +96.08%
Jun 6, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $48.18
Upside: -
Apr 5, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $1.96
Upside: -
Oct 8, 2021
Maintains: Strong Buy
Price Target: $50 → $65
Current: $44.20
Upside: +47.06%
Dec 1, 2020
Downgrades: Market Perform
Price Target: n/a
Current: $6.75
Upside: -
Oct 26, 2020
Upgrades: Outperform
Price Target: $255
Current: $274.76
Upside: -7.19%
Sep 10, 2018
Assumes: Buy
Price Target: $32
Current: $3.35
Upside: +855.22%
Jul 21, 2017
Downgrades: Sell
Price Target: n/a
Current: $154.14
Upside: -